162 related articles for article (PubMed ID: 29488249)
1. Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials.
Sun Y; Qi L; Yang G; Gilbert PB
Biom J; 2018 May; 60(3):516-536. PubMed ID: 29488249
[TBL] [Abstract][Full Text] [Related]
2. Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.
Gilbert PB; Sun Y
J R Stat Soc Ser C Appl Stat; 2015 Jan; 64(1):49-73. PubMed ID: 25641990
[TBL] [Abstract][Full Text] [Related]
3. Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials.
Yang G; Sun Y; Qi L; Gilbert PB
Stat Biosci; 2017 Jun; 9(1):259-283. PubMed ID: 28781713
[TBL] [Abstract][Full Text] [Related]
4. Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.
Sun Y; Gilbert PB
Scand Stat Theory Appl; 2012 Mar; 39(1):34-52. PubMed ID: 23519918
[TBL] [Abstract][Full Text] [Related]
5. Mark-specific hazard ratio model with missing multivariate marks.
Juraska M; Gilbert PB
Lifetime Data Anal; 2016 Oct; 22(4):606-25. PubMed ID: 26511033
[TBL] [Abstract][Full Text] [Related]
6. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
Juraska M; Gilbert PB
Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
[TBL] [Abstract][Full Text] [Related]
7. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
Sun Y; Li M; Gilbert PB
Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
[TBL] [Abstract][Full Text] [Related]
8. Mark-specific additive hazards regression with continuous marks.
Han D; Sun L; Sun Y; Qi L
Lifetime Data Anal; 2017 Jul; 23(3):467-494. PubMed ID: 27170333
[TBL] [Abstract][Full Text] [Related]
9. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
Gilbert PB; McKeague IW; Sun Y
Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
[TBL] [Abstract][Full Text] [Related]
10. Estimation of conditional cumulative incidence functions under generalized semiparametric regression models with missing covariates, with application to analysis of biomarker correlates in vaccine trials.
Sun Y; Heng F; Lee U; Gilbert PB
Can J Stat; 2023 Mar; 51(1):235-257. PubMed ID: 36937899
[TBL] [Abstract][Full Text] [Related]
11. Calibration weighted estimation of semiparametric transformation models for two-phase sampling.
Fong Y; Gilbert P
Stat Med; 2015 May; 34(10):1695-707. PubMed ID: 25648332
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Generalized Semiparametric Regression Models for Cumulative Incidence Functions with Missing Covariates.
Lee U; Sun Y; Scheike TH; Gilbert PB
Comput Stat Data Anal; 2018 Jun; 122():59-79. PubMed ID: 29892140
[TBL] [Abstract][Full Text] [Related]
13. Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.
Sun Y; Li M; Gilbert PB
Comput Stat Data Anal; 2016 Jan; 93():348-358. PubMed ID: 26461462
[TBL] [Abstract][Full Text] [Related]
14. Analysis of two-phase sampling data with semiparametric additive hazards models.
Sun Y; Qian X; Shou Q; Gilbert PB
Lifetime Data Anal; 2017 Jul; 23(3):377-399. PubMed ID: 26995733
[TBL] [Abstract][Full Text] [Related]
15. Variable selection for a mark-specific additive hazards model using the adaptive LASSO.
Han D; Qu L; Sun L; Sun Y
Stat Methods Med Res; 2021 Sep; 30(9):2017-2031. PubMed ID: 34266342
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes.
Heng F; Sun Y; Hyun S; Gilbert PB
Lifetime Data Anal; 2020 Oct; 26(4):731-760. PubMed ID: 32274677
[TBL] [Abstract][Full Text] [Related]
17. A Hybrid Approach for the Stratified Mark-Specific Proportional Hazards Model with Missing Covariates and Missing Marks, with Application to Vaccine Efficacy Trials.
Sun Y; Qi L; Heng F; Gilbert PB
J R Stat Soc Ser C Appl Stat; 2020 Aug; 69(4):791-814. PubMed ID: 33191955
[TBL] [Abstract][Full Text] [Related]
18. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
Li Z; Gilbert P; Nan B
Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
[TBL] [Abstract][Full Text] [Related]
19. Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variable.
Hudgens MG; Maathuis MH; Gilbert PB
Biometrics; 2007 Jun; 63(2):372-80. PubMed ID: 17688489
[TBL] [Abstract][Full Text] [Related]
20. Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials.
Gilbert PB; Yu X; Rotnitzky A
Stat Med; 2014 Mar; 33(6):901-17. PubMed ID: 24123289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
